KYNTRA BIO, INC.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
Business Address
350 BAY STREET, SAN FRANCISCO, CA, 94133
Mailing Address
350 BAY STREET, SAN FRANCISCO, CA, 94133
Phone
415-978-1200
Fiscal Year End
1231
EIN
770357827
Financial Overview
FY2025 FY
$29.62M
Revenue
$50.48M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 16, 2026 | View on SEC |
| 10-K Annual financial report | March 16, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| 4 Insider stock transaction report | March 10, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 17, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 8-K Current report of material events | January 7, 2026 | View on SEC |
| 4 Insider stock transaction report | December 9, 2025 | View on SEC |
| 4 Insider stock transaction report | December 9, 2025 | View on SEC |
Annual Reports
10-K
March 16, 2026
- Achieved strong revenue growth of 25% year-over-year, reaching $150 million in 2024.
- Strengthened by strategic partnerships with major pharmaceutical companies Astellas and AstraZeneca.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.